Tags

Type your tag names separated by a space and hit enter

Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.
Trop Med Infect Dis. 2020 May 15; 5(2)TM

Abstract

The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients.

Authors+Show Affiliations

Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK.School of Respiratory Medicine, University College London, London NW3 2PF, UK.Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK. School of Medicine, La Sapienza University, Rome 00185, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32429038

Citation

Oyelade, Tope, et al. "Prognosis of COVID-19 in Patients With Liver and Kidney Diseases: an Early Systematic Review and Meta-Analysis." Tropical Medicine and Infectious Disease, vol. 5, no. 2, 2020.
Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020;5(2).
Oyelade, T., Alqahtani, J., & Canciani, G. (2020). Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease, 5(2). https://doi.org/10.3390/tropicalmed5020080
Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients With Liver and Kidney Diseases: an Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020 May 15;5(2) PubMed PMID: 32429038.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. AU - Oyelade,Tope, AU - Alqahtani,Jaber, AU - Canciani,Gabriele, Y1 - 2020/05/15/ PY - 2020/04/26/received PY - 2020/05/10/revised PY - 2020/05/12/accepted PY - 2020/5/21/entrez PY - 2020/5/21/pubmed PY - 2020/5/21/medline KW - COVID-19 KW - SARS-CoV-2 KW - alcohol-related liver disease KW - chronic kidney disease KW - cirrhosis KW - hepatitis B and C KW - necrosis KW - nonalcoholic steatohepatitis JF - Tropical medicine and infectious disease JO - Trop Med Infect Dis VL - 5 IS - 2 N2 - The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients. SN - 2414-6366 UR - https://www.unboundmedicine.com/medline/citation/32429038/Prognosis_of_COVID_19_in_Patients_with_Liver_and_Kidney_Diseases:_An_Early_Systematic_Review_and_Meta_Analysis_ L2 - https://www.mdpi.com/resolver?pii=tropicalmed5020080 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.